NASD · Healthcare · Biotechnology · Israel
Pluri Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Pluri Inc is a biotechnology company leveraging its proprietary 3D cell expansion platform to develop cell-based products and therapies. The company operates across two areas: Human Health and Longevity, including placenta-derived cell therapy and immunotherapy candidates, plus development services; and Foodtech and Bio-Farming. Pluri maintains an industrial-scale GMP-compliant manufacturing facility.
From its FY2026 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Pluri Inc stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: not even its current assets cover what it owes.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on PLUR yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.